Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals is conducting a ...

This clinical study could significantly impact Regeneron and Intellia’s stock performance by showcasing their capabilities in gene therapy. Positive outcomes may enhance investor confidence and ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...